Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Objectives: Allergic Rhinitis (AR) is a global health problem. 10-25% of population worldwide
is affected by AR. Oral/intranasal H1-antihistamine, decongestants, leukotriene receptor
antagonists, intranasal corticosteroids are the pillars in the management of AR.Materials and
methods: Seventy patients with allergic rhinitis participated in a prospective, randomized,
double-blind, parallel, active controlled, comparative 4 week trial. The patients between age
group of 18-65 years of either gender having moderate-severe intermittent or mild persistent
allergic rhinitis were included. The study inclusion criteria required the subjects with
Total Nasal Symptom Score (TNSS) of 5 or higher. The patients were randomly divided into two
treatment groups with montelukast-levocetrizine (10 mg and 5 mg) in one group and
montelukast-fexofenadine (10 mg and 120 mg) in another group. TNSS parameter was the main
effectiveness parameter.
Phase:
Phase 4
Details
Lead Sponsor:
Indira Gandhi Medical College Indira Gandhi Medical College, Shimla